Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Study B 30-day comment period suggested by NDMA.

This article was originally published in The Tan Sheet

Executive Summary

"MEDICATION FACTS" HEADING DISCOURAGED BY NDMA in Feb. 13 comments to FDA on the agency's OTC Label Format Preference, "Study B." Noting that the "Medication Facts" heading was not mentioned in the agency's proposed rule on OTC label reform and the Study B data were presented in a manner difficult to analyze, the Nonprescription Drug Manufacturers Association recommends "FDA either re-propose this aspect of the labeling proposal or, preferably in the alternative, be silent about the use of `Medication Facts' in the final rule and make no further proposals on this matter."
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS088132

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel